tiprankstipranks
Halozyme backs FY24 adjusted EPS view $3.55-$3.90, consensus $3.51
PremiumThe FlyHalozyme backs FY24 adjusted EPS view $3.55-$3.90, consensus $3.51
2M ago
Halozyme reports Q4 adjusted EPS 82c, consensus 82c
PremiumThe Fly
Halozyme reports Q4 adjusted EPS 82c, consensus 82c
2M ago
Halozyme announces Takeda received EC approval for HYQVIA
PremiumThe Fly
Halozyme announces Takeda received EC approval for HYQVIA
3M ago
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
PremiumPress ReleasesHalozyme to Host Investor Business Forum and Long-Term Outlook Call
3M ago
Halozyme price target lowered to $59 from $61 at Morgan Stanley
PremiumThe Fly
Halozyme price target lowered to $59 from $61 at Morgan Stanley
4M ago
Halozyme price target lowered to $45 from $46 at Goldman Sachs
PremiumThe Fly
Halozyme price target lowered to $45 from $46 at Goldman Sachs
4M ago
Halozyme reports Q3 adjusted EPS 75c, consensus 73c
PremiumThe FlyHalozyme reports Q3 adjusted EPS 75c, consensus 73c
5M ago
Acumen, Halozyme enter global collaboration, license agreement
PremiumThe Fly
Acumen, Halozyme enter global collaboration, license agreement
5M ago
Halozyme enters non-exclusive license agreement with Acumen Pharmaceuticals
PremiumThe Fly
Halozyme enters non-exclusive license agreement with Acumen Pharmaceuticals
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100